English

• 1. [1]Xiong CL,Zhang YZ,Lu SQ,et al.Advances in the study of biological characteristics of rabies virus[J].Chinese J Epidemiol,2006,27(10):913.(in Chinses)熊成龙,张永振,卢思奇,等.狂犬病病毒生物学特征研究进展[J].中华流行病学杂志,2006,27(10):913. [2]WHO Expert consultation on rabies,5-8 October 2004.Technical report series 931 first report.Accessed at http://www.who.int/rabies/931/en/index.html. [3]Tang JQ.Natural focus diseases[M].Beijing:Science Press,2005:358-392.(in Chinese)唐家琪.自然疫源性疾病[M].北京:科学出版社,2005:358-392. [4]Yusibov V,Hooper DC,Spitsin sv,et al.Expression in plants and immunogenicity of plant vires based experimental rabies[J].Vaccine,2002,20(25-26):3155-3164. [5]Lin HX,Perrin P.The effect of aluminum adjuvants on experimental rabies vaccine[J].Chinese J Exp Clini Virol,1999,2(13):133-135.(in Chinese)林海祥,Perrin P.铝佐剂对实验狂犬病疫苗的影响[J].中华实验和临床病毒学杂志,1999,2(13):133-135. [6]Yan JX,Li CP,Zhu JH,et al Establishment of the rapid fluorescent focus inhibition test(RFFIT) for the detection of the antibodies to rabiesvirus[J].Chinese J Biol,1998,11(2):93-96.(in Chinese)严家新,李承平,朱家鸿,等.检测狂犬病毒中和抗体的快速荧光灶抑制试验(RFFIT)方法的建立[J].中国生物制品学杂志,1998,11(2):93-96. [7]Lodmell DL,Ray NB,Ulrich JT,et al.DNA vaccination of mice against rabies virus:effects of the route of vaccination and the adjuvant monophosphoryl lipid A(MPL)[J].Vaccine,2000,18(11-12):1059-1066. [8]Guo XX,Yang Q,Liu Y,et al Immune effect of rabies virus liposome vaccine for human use[J].Chinese J Biol,2007,20(2):107-109.(in Chinese)郭秀侠,杨倩,刘岩,等.人用狂犬病脂质体疫苗的免疫效果[J].中国生物制品学杂志,2007,20(2):107-109. [9]Castignolles N,Morgeaux S,Gontier-Jallet C,et al.A new family of carriers (biovectors) enhances the immunogenicity of rabiesantigens[J].Vaccine,1996,14(14):1353-1360. [10]Cui YG,Wu XJ,Guo Y,et al.The effect of astragalus polysacharin(APS) on the immunogenicity of rabies vaccine for human use[J].Chinese J Biol 2006,19(5):492-496.(in Chinese)崔颖杰,吴晓娟,郭岩,等.黄芪多糖对人用狂犬病疫苗免疫原性的影响[J].中国生物制品学杂志,2006,19(5):492-496. [11]Zou Y,Song JP,Lv HI,et al.Immunogenicity and curative effect of rabies vaccine-interferon combined preparation[J].Chinese J Biol,2002,15(5):287-289.(in Chinese)邹勇,宋继萍,吕宏亮,等.狂犬病-干扰素联合制剂的免疫原性及治疗作用[J].中国生物制品学杂志,2002,15(5):287-289. [12]Leroy M,Pine G,Baise E,et al.Expression of the interferon-alpha/beta indueible bevine Mxl dynamin interferes with replication of rabies virus[J].Neurobiol Dis,2006,21(3):515-521. [13]Chávez JH,teal PC,Yunes RA,et al.Evaluation of antiviralactivity of phenohc compounds and derivatives against rabies virus[J].Vet Microbiol,2006,116(1-3):53-59. [14]Chavanet P,Sureau P,Waldner-Combernoux A,et al.A simplified method of vaccination against rabies after exposure[J].Presse Med,1989,18(16):813-815. [15]Chutivongse S,Wilde H,Fishbein DB,et al.One-year study of the 2-1-1 intramuscular pest exposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and vero cell rabies vaccine[J].Vaccine,1991,9(8):573-576. [16]Gao GX,Li CZ,Wu TC,et al.Observation of the immune effects of rabies vaccine in different immunization schedules and injection methods[J].Gnansxi J Prey Med,2001,7(4):234-235.(inChinese)高贵霞,李冲之,吴泰才,等.狂犬疫苗不同免疫程序和注射方法的免疫效果观察[J].广西预防医学,2001,7(4):234-235. [17]Khawplod P,Wilde H,Sirkwin S,et al.Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection[J].Vaccine,2006,24(16):3084-3086. [18]Madhusadana SN,Anand NP,Shamsundar R.Evaluation of twointradermal vaccination regimens using purified chick embryo cell vaccine for post-exposure prophylaxis of rabies[J].Natl Med J India,2001,14(3):145-147. [19]Ambrozaitis A,Laiskonis A,Balciuniene L,et al.Rabies post-ex-posure prophylaxis vaccination with purified chick embryo cellvaccine (PCECV) and purified vero cell rabies vaccine (PVRV)in a four-site intradermal schedule (4-0-2-0-1-1):An immunogenie,cost-effective and practical regimen[J].Vaccine,2006,24(19):4116-4121. [20]Sudarshan MK,Madhusudana SN,Mahendra BJ,et al.Boostingeffect of purified chick embryo cell rabies vaccine using the intradermal route in persons previously immunized by the intramuscular route or vice versa[J].Natl Med J ladis,2006,19(4):192-194. [21]Intradermal application of rabies vaccines.Report of a WHO consultation.Bangkok,Thailand 5-6 June 2000.Accessed at http://www.who.int/entity/rabies/en/Report_WHO_consultation_on_intradermal_application_of_human_rabies_vaccines.pdf. [22]Chhabra M,Ichhpujani RL,Bhardwaj M,et al.Safety and immunogenicity of the intradernud Thai Red Cross(2-2-2-0-1-1)postexposure vaccination rogimen in the Indian population using Purified chick embryo cell rabies vaccine[J].Indian J Med Microbiol,2005,23(1):24-28. [23]Lang J,Attanath P,Quiambao B,et al.Evaluation of the safety,immunogenicity,and pharmacokinetic profile of a new,highly purified,heat-treated equine rabies immunoglobulin,administered either alone or in association with a purified,Vero-cell rabies vaccine[J].Aeta Trop,1998,(70):317-333. [24]Schumacher CL Dietzschold B,Ertl HC,et al.Use of mouse antirabies monoclonal antibodies in post exposure treatment of rabies[J].J Clin Invest,1989,84(3):971-975. [25]Goudsmit J,Marissen WE,Weldon WC,et al.Comparison of antirabies human monoclonal antibody combination with human palyelonal anti-rabies immune globulin[J].Infec Dis,2006,193(6):796-801. [26]Sloan SE,Hanlon C,Weldon W,et al.Identification and charactefization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolares[J].Vaccine,2007,25(15):2800-2810. [27]Khawplod P,wilde H,Tepsumethanon S et al.Prospective Immunogenicity Study of Multiple Intradermal Injections of Rabies Vaccine in an Effort to Obrain an Early Immune Response without the Use of Immunoglobulin[J].Clin Infec Dis,2002,35(12):1562-1565. [28]Belotto A,Leanes LF,Schneider MC,et al.Overview of rabies in the Americas[J].Virus Res,2005(111):5-12. [29]Middaugh J,Bitter D.A comprehensive rabies control program in Alaska[J].AM J Public Health,1982,72(4):384-386. [30]Wan GR,Zhang L.Implementation of the rabies immune provention notification scheine and observations of its effects[J].Modern Prey Med,2007,34(10):1970.万桂荣,张林.狂犬病免疫预防告知制的实施及效果观察[J].现代预防医学,2007,34(10):1970.
     

• 1. [1]

     龚震宇 , 杨小平 . 世界卫生组织关于狂犬病疫苗的意见书. 疾病监测, 2012, 27(2): 166-168.

  2. [2]

     韩庆英 , 高洁 , 马书花 , 侯文俊 , 袁明 , 李洁 , 石春兰 , 常庆红 , 王福珍 , 龚晓红 . 北京市大兴区3-12岁儿童乙型肝炎疫苗免后流行病学效果观察. 疾病监测, 2004, 19(10): 365-368. DOI: 10.3784/j.issn.1003-9961.2004.10.365

  3. [3]

     龚震宇 , 龚训良 . WHO关于登革热疫苗的意见书(摘要)(2016年7月). 疾病监测, 2016, 31(12): 1076-1078. DOI: 10.3784/j.issn.1003-9961.2016.12.022

  4. [4]

     董珊 , 黄群艳 . 1270例注射人用狂犬病纯化疫苗者免疫效果观察. 疾病监测, 2005, 20(11): 579-581. DOI: 10.3784/j.issn.1003-9961.2005.11.579

  5. [5]

     龚震宇 , 杨小平 . 世界卫生组织关于狂犬病疫苗的最新意见. 疾病监测, 2009, 24(6): 472-474. DOI: 10.3784/j.issn.1003-9961.2009.06.029

  6. [6]

     许真 , 唐青 , 宋淼 , 殷文武 , 王茂武 ,  . 2005年中国人间狂犬病流行特征及分析. 疾病监测, 2006, 21(7): 360-365. DOI: 10.3784/j.issn.1003-9961.2006.7.360

  7. [7]

     龚震宇 , 龚训良 . 2015年全球犬传播的人类狂犬病流行现况. 疾病监测, 2016, 31(3): 263-264. DOI: 10.3784/j.issn.1003-9961.2016.03.019

  8. [8]

     龚震宇（摘译） , 龚训良（审校） . 美国1938－2018年人类狂犬病暴露和死亡的趋势分析. 疾病监测, 2019, 34(10): 953-954. DOI: 10.3784/j.issn.1003-9961.2019.10.020

  9. [9]

     高洁 , 何永频 , 沈冰 , 胡宏 , 卑伟慧 , 徐翠伟 . 上海市静安区60岁以上老年人接种 23价肺炎球菌多糖疫苗效果评估. 疾病监测, 2015, 30(7): 582-584. DOI: 10.3784/j.issn.1003-9961.2015.07.014

  10. [10]

      周红 , 丛旭芝 , 唐前华 , 李洪彦 . 2006年贵州省六盘水市48例狂犬病疫情流行因素分析. 疾病监测, 2007, 22(7): 471-472. DOI: 10.3784/j.issn.1003-9961.2007.7.471

  11. [11]

      姚军 , 陈永弟 , 楼滨 , 任菁菁 . 不同剂量乙型病毒性肝炎疫苗母婴阻断效果评价. 疾病监测, 2010, 25(12): 981-983. DOI: 10.3784/j.issn.1003-9961.2010.12.016

  12. [12]

      沈灵智 , 陈永弟 , 蒋征刚 , 李倩 , 陈恩富 , 梁晓峰 , 崔富强 , 姚军 . 不同剂次重组乙型病毒性肝炎疫苗(汉逊酵母)加强免疫效果研究. 疾病监测, 2011, 26(10): 811-814.

  13. [13]

      蒋征刚 , 陈永弟 , 陈恩富 , 李倩 , 唐学雯 , 姚军 . 基因工程乙型病毒性肝炎疫苗基础免疫5~11年后抗体阴性儿童加强免疫效果分析. 疾病监测, 2011, 26(9): 679-681.

  14. [14]

      蓝岳云 , 姜宪尘 . 浙江省衢州市甲型病毒性肝炎免疫接种的流行病学效果评估. 疾病监测, 2015, 30(9): 749-753. DOI: 10.3784/j.issn.1003-9961.2015.09.012

  15. [15]

      李景越 . 2011－2019年河南省南阳市112例儿童艾滋病抗病毒治疗效果分析. 疾病监测, 2020, 35(9): 1-4.

  16. [16]

      王骥涛 , 石洁平 , 张晓林 , 张拉弟 , 孙樯 , 韩建荣 . 2005-2007年太原市部分狂犬病疫苗接种者狂犬病病毒抗体检测结果分析. 疾病监测, 2009, 24(6): 396-397. DOI: 10.3784/j.issn.1003-9961.2009.06.004

  17. [17]

      马超 , 郝利新 , 苏琪茹 , 温宁 , 樊春祥 , 杨宏 , 李黎 , 王华庆 . 中国2014年麻疹流行病学特征分析. 疾病监测, 2015, 30(10): 818-823. DOI: 10.3784/j.issn.1003-9961.2015.10.006

  18. [18]

      陆家华 , 吴泰才 . 广西45年狂犬病疫情动态与防制效果分析. 疾病监测, 1997, 12(11): 408-413. DOI: 10.3784/j.issn.1003-9961.1997.11.408

  19. [19]

      吴泰才 , 葛宪民 , 王学燕 , 黄德惠 . 1997年中国部分省狂犬病疫情回升与疫苗质量下降关系. 疾病监测, 1999, 14(9): 327-331. DOI: 10.3784/j.issn.1003-9961.1999.9.327

  20. [20]

      专题协作组 . 中国肾综合征出血热疫苗近期防病效果. 疾病监测, 1996, 11(3): 85-88. DOI: 10.3784/j.issn.1003-9961.1996.3.85

•